SELLAS Life Sciences (SLS) Free Cash Flow Growth (3y) (2013 - 2026)
SELLAS Life Sciences (SLS) Free Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,921.77 Bn | 66,921.49 Bn | - | -5.05% |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.57 Bn | 466.77 Bn | 1.35 Bn | 31.07% |
| 5 | Vertex Pharmaceuticals | 122.01 Bn | 114.76 Bn | 2.59 Bn | 14.71% |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn | -10.65% |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.86 Bn | 50.68 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.48 Bn | 34.47 Bn | 959.66 Mn | 31.42% |
| 10 | SELLAS Life Sciences | 1.84 Bn | 1.74 Bn | - | 10.14% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.14% |
| Dec 31, 2025 | 1.44% |
| Sep 30, 2025 | -7.15% |
| Jun 30, 2025 | -8.36% |
| Mar 31, 2025 | -8.25% |
| Dec 31, 2024 | -12.86% |
| Sep 30, 2024 | -9.92% |
| Jun 30, 2024 | -25.50% |
| Mar 31, 2024 | -1.57% |
| Dec 31, 2023 | -50.50% |
| Sep 30, 2023 | -23.84% |
| Jun 30, 2023 | -30.80% |
| Mar 31, 2023 | -21.08% |
| Dec 31, 2022 | -7.25% |
| Sep 30, 2022 | -14.58% |
| Jun 30, 2022 | -7.36% |
| Mar 31, 2022 | -12.73% |
| Dec 31, 2021 | -2.99% |
| Sep 30, 2021 | 25.41% |
| Jun 30, 2021 | 8.04% |